Ambros Therapeutics Announces New U.S. Patent for Neridronate in Complex Regional Pain Syndrome

Patent Allowance Strengthens Exclusivity Potential for Orphan Drug Candidate Through 2045

Mar. 31, 2026 at 2:09pm

Got story updates? Submit your updates here. ›

A highly detailed, translucent X-ray photograph showing the intricate bone and tissue structures of a human hand or foot, conveying the complex neurological underpinnings of CRPS-1 through a ghostly, ethereal visual style.An innovative X-ray imaging technique sheds light on the complex neurological mechanisms behind the debilitating symptoms of Complex Regional Pain Syndrome.Irvine Today

Ambros Therapeutics, a clinical-stage biotech company, announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a new patent application covering methods of selectively treating patients with Complex Regional Pain Syndrome Type 1 (CRPS-1) using the company's investigational drug neridronate. This patent will enhance Ambros' intellectual property portfolio and potentially extend exclusivity for neridronate through 2045.

Why it matters

CRPS-1 is a rare and debilitating condition with no FDA-approved treatments. The new patent represents an important step for Ambros and its neridronate program, as it could provide meaningful value for patients, investors, and other stakeholders by strengthening the company's position to advance this potential first-in-class therapy for CRPS-1.

The details

The allowed patent application covers combining a positive triple-phase bone scan (TPBS) and specific attributes of the 'warm' CRPS subtype as a method for selecting likely responders to neridronate treatment. Ambros is using these same patient selection criteria as part of the eligibility determination in its ongoing pivotal Phase 3 CRPS-RISE clinical trial of neridronate.

  • Ambros filed the patent application in July 2025.
  • Ambros initiated enrollment in the CRPS-RISE Phase 3 trial in the first quarter of 2026.

The players

Ambros Therapeutics

A clinical-stage biotechnology company focused on developing innovative medicines for diseases with high unmet medical need, including neridronate for the treatment of CRPS-1.

Jay Hagan

Chief Executive Officer of Ambros Therapeutics.

Gail Cawkwell, M.D., Ph.D.

Chief Medical Officer of Ambros Therapeutics.

Got photos? Submit your photos here. ›

What they’re saying

“The granting of this patent will mark an important step for Ambros and our orphan drug neridronate, and represents the potential for meaningful value creation among patients, investors and all stakeholders.”

— Jay Hagan, Chief Executive Officer of Ambros Therapeutics

“Supported by innovative analyses of data, the methods of patient selection covered by this allowed patent application represent a novel precision medicine approach to identifying patients with CRPS-1 who are likely to respond to neridronate.”

— Gail Cawkwell, M.D., Ph.D., Chief Medical Officer of Ambros Therapeutics

What’s next

Ambros plans to continue advancing the neridronate program through its pivotal CRPS-RISE Phase 3 clinical trial, which was initiated in the first quarter of 2026 using the patient selection criteria covered by the newly allowed patent.

The takeaway

This patent allowance represents an important milestone for Ambros and its neridronate program, as it strengthens the company's intellectual property position and could help extend exclusivity for this potential first-in-class treatment for the rare and debilitating condition of CRPS-1, which currently has no FDA-approved therapies.